Telstar ACE welcomes new Technical Manager

Telstar ACE welcomes new Technical Manager

July 2010 . Number 21
T
G ELS
RO T
A
U R
P
www.telstar.eu
Telstar acquires Usifroid and takes a major step
into the French market
Telstar has acquired French company Usifroid, which is internationally recognized for the development
and supply of GMP lyophilizers for the pharmaceutical market.
Through this acquisition, on April 9th 2010,
Telstar reinforces its position in the
international life sciences market and
consolidates its position in Europe with a
French market share of 80% in freeze drying
equipment solutions for the pharmaceutical
industry.
This acquisition will enable the Telstar Group
to pursue its strategic growth plan while
providing the backing and financial support
to enable Usifroid in France to continue
supplying and serving its customers on the
French and international markets. Usifroid is
internationally renowned for the
development of GMP freeze dryers of
pharmaceutical applications and is
recognized for achievements in the field of
innovation, most notably for pioneering and
leading the use of liquid nitrogen (LN2)
refrigeration technology in freeze drying.
The reputation and significance of the
Usifroid brand is reflected through the
constant references to the activities of the
company therefore the Telstar Group will
retain the Usifroid brand and Usifroid
products in all the markets. Usifroid will
continue to provide new equipment under
the Usifroid brand, with specifications and
features that help characterize and define
Usifroid.
freeze drying technology, includes a wide
range of solutions orientated towards the
pharmaceutical industry such as clean air,
containment, sterilisation and water
treatment. In fact, the Telstar Group is
recognized as one of the few companies in
the world capable of supplying integrated
process solutions through in-house
technologies which address the needs of the
pharmaceutical industry.
The Telstar Group will incorporate the knowhow and experience of Usifroid so that
Usifroid equipment becomes an integral part
of the Telstar portfolio, which, in addition to
Editorial
Corporate Management of Key Accounts
Life Science Solutions
Telstar Group
• Telstar reinforces its commercial structure for the life sciences market
Back Cover
• Exhibitions and Conferences
Vacuum Solutions
TPro
• Telstar Vacuum Solutions supply
leak detection equipment
for
Stirling motors.
• Cristalia inaugurates a new
multipurpose production plant.
• Telstar incorporates Ferran Costas
as General Manager of Telstar
Vacuum Solutions.
• The United Pharmaceutical
Technologies Consortium for large
process projects in the field of life
sciences is being created in Brazil.
LABORATORY
• Telstar launches new generation of
more compact biological safety
cabinets that optimize laboratory
space.
• Telstar introduces into the
international market the first
minibioreactors allowing multiple
simultaneous cell culture trials.
PHARMA
• Integrating ergonomic trials into the
design process.
• Telstar ACE welcomes new Technical
Manager.
• Telstar broadens its industrial freezedryer product range.
• Telstar develops isolated lyophilizer
loading/unloading system for bulk
product.
EDITORIAL
TPRO
Corporate Management of Key Accounts
Cristalia inaugurates a new multipurpose production plant
Telstar as a strategic technological partner of its clients.
The pharmaceutical company Cristalia, founded in 1972 and based in the city of São Paulo, has invested in
one of the most modern and innovative drug production plants in Brazil.
The globalisation of
the market has made
commonplace the
development of
complex projects
involving a large
number of partners
located across a
number of countries.
Good management of these projects
requires the free flow of communication
between each and every one of them, along
with sound internal co-ordination to achieve
the best outcome rapidly and efficiently.
The current structure of the Telstar Group,
with production plants covering different
technologies in various countries with
various representatives at the commercial
level increases the need for co-ordination to
convey information consistently and clearly.
It is in this environment that the corporate
key account manager is of utmost
importance as the link between the client's
organisation and Telstar, to provide and
ensure communication, knowledge and, in
short, client satisfaction. Telstar would like
clients to see it as a strategic technological
partner and not merely as an equipment
and/or services provider.
Telstar is growing, its clients are growing and
its project base is growing. From this
standpoint, the Telstar Group has enhanced
its organisational model, placing particular
importance on client-based management
and the creation of synergies to serve client
interests effectively and efficiently. This is an
all-embracing function that had hitherto
been developing separately but which is now
being consolidated at a global level,
promoting mutual co-ordination of all the
activities of the various Telstar companies
and centres in the field of Life Sciences and in
particular everything in relation to the
pharmaceutical and bio-technology sectors.
The main objective is, therefore, client
satisfaction through the implementation of
procedures to ensure an unrivalled service.
The Telstar motto: Focus on the client. Telstar
wants to co-ordinate actions and projects
and strive to guarantee that information
flows correctly, not only within the Telstar
organisation, but also to clients. “We will
improve clients' knowledge of our
organisation and the solutions that we can
offer them, improving our knowledge of their
organisations and requirements in order to
cement the relationship seen in the long
term. In short, we aim to create the ability to
provide a quality solution that contributes to
the growth and development of our clients”.
Toni Lorente,
Corporate Key Account Manager
TELSTAR GROUP
Telstar reinforces its commercial structure for the life
sciences market
To this end, two commercial teams working
in the Pharmaceutical Industry and
Laboratory fields will be responsible for the
promotion and sale of the whole range of
equipment, projects, systems and services
and will be able to provide complete or
individual solutions with a global and process
perspective according to market
requirements and client needs.
Currently, Telstar is one of the few company
groups in the world that can provide
integrated solutions in the process field for
the life sciences market.
This new organisation is headed by the
Corporate Sales and Marketing Director,
Jordi Puig, along with a new management
team. The Pharma team includes Toni
Lorente as Corporate Major Accounts
Director, Jordi Net as Commercial and
Marketing Director for Pharmaceutical
Industry Teams and Rafael Alvarez de Toledo
as Commercial and Marketing Director for
Project Development.
The Laboratory team consists of Chantal
Schoenmaker as Commercial Director for
Central and Northern Europe and Roser
Dalmau as Commercial Director for the Rest
of the World.
Cristalia continuously invests in offering
innovative products for the Brazilian
market. It has registered 117 patent
applications and has patents for 21
technologies and 15 drugs, making it the
national drug company with the largest
number of patents.
The management made the decision to
expand production capacity five years
ago, through the construction of a new
unit in Itapira, São Paulo. It will be the
second drug production plant on this site,
where operation is already underway in
the areas of R&D and innovation,
biotechnology and pharmaceutics. This is
in addition to the current drug plant,
2
which has over 53,000 m of constructed
surface. In order to acquire the latest
technologies for the new factory,
company management participated in
various international fairs and technical
visits in 2003 and 2004.
Through these actions, the company
established the highest standards of
architectural, material and equipment
solutions. Conceptually, the aim was to
construct a compact unit, with the
maximum level of process optimization
and functionality in space. This was
achieved by incorporating the most
modern concepts and equipment.
In the outcome, TPRO was designated by
Cristalia as the specialised company for
this development. The pharmaceutical
2
plant covers close to 11,800 m of
constructed production surface, from
2
which 3,100 m correspond to classified
areas, and the rest to technical surfaces
and controlled areas. The new facility will
allow Cristalia to double its current
production capacity.
In general terms, there are four specific
areas: sterile freeze-dried products,
sterile liquids (eyedrops), oral solids and
semi-solids (ointments). On the first floor,
most of the space is used for the
production of freeze-dried (lyophilized)
products. This comprises close to
2
1,470 m , 540 of which correspond to
classified areas and 930 to non-classified
areas. The solids production unit is the
largest of all; the production line occupies
2
2,600 m , of which 1,500 correspond to
Grade D and the rest to non-classified
areas.
The new facility of Cristalia is among the
most modern and efficient in the world
and the final result is a world class
production plant.
The United Pharmaceutical Technologies Consortium for
large process projects in the field of life sciences is being
created in Brazil
Combining the synergies that exist between Pharmaster, Tpro and SVS will bring greater competitive value to
large scale projects in the pharmaceutical industry.
The Telstar Group is reinforcing its commercial structure for the
Pharmaceutical Industry and Laboratory divisions by incorporating the
various commercial teams that hitherto have been separated along
product or geographical lines into a single sales and marketing force.
This new strategy, which enhances the
Group's ability to provide a global response
to market requirements, will bring increased
efficiency, depth and coverage to the
growing presence of the Telstar Group in the
international life sciences market.
The facility, which was officially
inaugurated last March, has increased the
production capacity of the company and
readied it for further challenges.
R. Alvarez de Toledo
T. Lorente
J. Puig
R. Dalmau
The companies Pharmaster, Tpro Engenharia
do Brasil and SVS Consulting Services have
reached an agreement to create the United
Pharmaceutical Technologies Consortium in
order to provide highly competitive solutions
for projects associated with the Life Sciences
industries.
J. Net
The combination of synergies and the
complementary attributes of the three
companies will enable the rapid
development of sound technical
solutions for the design, installation,
commissioning and evaluation of systems
critical to the pharmaceuticals, biotechnologies, cosmetics and veterinary
industries, directed in particular towards
larger and more complex projects.
C. Schoemaker
The companies making up the consortium
have a substantial penetration and presence
in the Brazilian market. Complementary
resources and know-how will bring particular
benefits to medium and large volume
projects, providing competitive advantages
derived from the combination of synergies
of the three companies. The United
Pharmaceutical Technologies Consortium
can provide the design, installation,
evaluation and commissioning of not only a
specific unit, but also a complete plant,
including engineering, installation,
evaluation and certification and
management services.
This partnership agreement does not
signify the loss of identity of any of the
companies making up the consortium. Each
one will maintain its independence and its
own commitments. In fact, each one of the
companies of the consortium will continue
to operate autonomously and independently
in the market, supporting projects of small
and medium sized companies, just as they
have been doing up to now.
VACUUM SOLUTIONS
LIFE SCIENCE SOLUTIONS - Laboratory
Efficient Home Energy, belonging to the Mondragón group, manufactures the Stirling energy microgeneration
boiler.
This is a normal-sized domestic boiler with a
combined heat and electricity
microgenerating system, running on gas,
which besides covering domestic heating and
hot water needs also generates electricity.
Its impellers are capable of reducing home
energy bills by over 20%, and cutting CO2-
emissions by up to a tonne a year per
household.
The Stirling principle comes from an invention
in 1816 by a Scottish religious minister of that
name. Basically it is a motor which runs on hot
air. The expansion induced within a gas moves
a working piston which drives a dynamo.
With domestic heating boilers, use is made of
the combustion exhaust gases which are lost
up the flue. The movement of the pistons is
converted into electricity generation which is
fed into the grid. It is therefore an “energy
saving” system which means energy can be
saved in every home.
Telstar launches new generation of more
compact biological safety cabinets that optimize
laboratory space
!
ew
N
Telstar Vacuum Solutions supply leak detection
equipment for Stirling motors
Telstar has released an innovative cabinet design, which maintains work
space while making the chassis up to 20% smaller than the market average.
Telstar has developed a new generation of
biological safety cabinets, which are more
compact and optimise the usable work area in
laboratories with limited space. Intended for
the laminar flow manipulation of
microorganisms with biological risk levels 2
and 3, the new range of Telstar Bio II Advance
cabinets offers an ergonomic design that
adapts easily to small spaces, especially in
laboratories with low ceilings and where
various pieces of equipment need to be used
in the same area.
With all the features of a high-end cabinet, the
Bio II Advance is designed to protect the user,
the sample and the environment, and is
notable for its reduced external dimensions
while maintaining an optimum inner work
space. With a width of 759 mm, the height of
the Bio II Advance is up to 20% less than the
market average.
The Bio II Advance also incorporates
improvements in airflow efficiency. The
reduction of the air path in an optimised
plenum, combined with automatic
microprocessor control, keeps the laminar
flow constant and avoids energy loss, reducing
heat dissipation and extending the useful life of
the filter. As for energy efficiency, this range of
cabinets has an Eco Mode function, whereby
the cabinet can be put on standby, which
keeps the sample protected inside the cabinet
while the user performs other tasks, saving
energy, reducing residual heat and prolonging
the useful life of the filters. Finally, in this range
of biosafety cabinets, Telstar has incorporated
the 4F system (Fast, Friendly and eFFicient), a
patented system that makes it possible to
replace the filter in just five minutes thanks to
quick access via the front of the cabinet.
N
ew
!
Telstar introduces into the international market
the first minibioreactors allowing multiple
simultaneous cell culture trials
Telstar incorporates Ferran Costas as General Manager of
Telstar Vacuum Solutions
Ferran Costas has joined the Telstar Group as general manager of Telstar Vacuum Solutions.
Ferran is a Telecommunications Engineer
specialising in the
development of specific
projects for the
aerospace sector, with
an MBA from Esden
(Madrid).
Ferran brings with him a wealth of experience
in the design and development of
RF/microwave equipment and sub-systems for
satellites such as Hispasat-Amazonas, Galileo,
SMOS, ICO, Terrestar, Globalstar-2, etc. His
professional career includes positions with
Mier Communications, which designs and
produces radio frequency communication
equipment and systems, as well as with
Ingenieria de Radiofrecuencias (Radio
Frequency Engineering) – IRSA, TRACOR SA,
Radiación Microondas SA (Microwave
Radiation) – RYMSA, where he acted as
deputy general manager, and Arthur Andersen.
In his new role with Telstar Vacuum Solutions,
Ferran will direct Group strategy in the field of
high vacuum and ultra high vacuum project
development to consolidate the Group's
position in the international market and
reinforce the growth plans in the hightechnology energy, aerospace and scientific
research industries market. The focus will be
on development of high added value products
and projects with an engineering and
innovation component, specifically in the area
of space simulators for space companies,
agencies and institutions, and of large scientific
installations in various fields: nuclear fusion,
particle accelerators (synchrotrons, neutron
sources, etc.) and large telescopes (for
example, reflector recoating plants). Also,
within the framework of this new step, there
will be a commitment from Telstar Vacuum
Solutions to promote the development of
vacuum and high vacuum technology
equipment for industrial applications, in
particular those incorporating high levels of
technology.
Telstar has developed a sound track record in
the development of space technology, high
vacuum and ultra-high vacuum technology
following involvement in large scale projects
that have taken place in recent years which
have earned it international recognition and
distinction.
Of particular note is its participation in the
development of international projects, such as
synchrotrons (ESRF, ALBA), space simulation
chambers and the experimental nuclear fusion
reactor, ITER. In fact, Telstar was the first
company in the world to design and
manufacture the mechanical manipulator for
the future international reactor, ITER and
recently developed the largest space
simulation chamber in the southern
hemisphere for the Government of Brazil
(INPE).
Telstar is introducing into the market a completely innovative minibioreactor model to perform animal cell culture
screening studies on a scale applicable to R&D. Planned for 2010, this equipment will be launched on the market under
the brand name of Telstar Hexascreen.
It is the first minibioreactor on the market to
enable animal cell culture trials and
experiments on a scale of 10 to 15 m, with the
capacity to handle six cultures at a time, and a
workstation accommodating single-use
interchangeable plates to guarantee sterility
and speed up the start of the bioprocess.
The launch of this new bioreactor reinforces
Telstar's activity in the field of R&D equipment
for biotechnology applications. The new
minibioreactor will be included in the
technological development line Telstar Cell
Culture, where Telstar has plans for future
growth. Telstar is currently designing,
manufacturing and marketing other
equipment designed for pharmaceutical,
biotechnological and biomedical research, to
which it will be adding the new range of Telstar
Hexascreen minibioreactors.
The development of these minibioreactors is
the result of an alliance of synergies between
Telstar and the technology oriented company
Hexascreen Culture Technologies, which
specializes in bioreactor applications for
animal cell based processes, which Telstar
recently joined through a shareholding
acquisition.
Innovative equipment
These units offer change of medium,
monitoring and control facilities similar to
those of laboratory reactors, which enable the
collection of information on the main culture
variables, such as the temperature, dissolved
oxygen/oxygen consumption, pH, optical
density and measurement of the spectrum in
the visible range, while simultaneously
monitoring growth (absorbance) and
metabolism (indirectly from acidification/
oxygen consumption).
All these features make the Telstar Hexascreen
the most innovative equipment for the
pharmaceutical and biotechnology industry
market and research centers because:
• It offers the user reduced cost by being able
to carry out the first trials on a minimum scale
in order to ensure that the results obtained in
its cultures will be reproducible on a
production scale.
• It speeds up the bioprocess and multiples the
opportunities for experimentation by being
able to develop six simultaneous cultures.
• It facilitates the start of the bioprocess by the
use of replaceable plates which ensure sterility,
requiring the user merely to inoculate the
cultures before placing the plate in the
workstation. This innovation overcomes the
complexity of use usually found in bioreactors,
which involve laborious preparation,
sterilization and calibration processes before
the start of the cultures, often requiring highly
qualified personnel.
During 2010, Telstar will develop a new stage
in the Telstar Hexascreen minibioreactor by
incorporating the fed-batch model for growth
and increased productivity of the cell culture.
Collaboration with universities and
technological leadership
Telstar's leadership in the innovation and
development of new technologies in the field
of life sciences is the result of an ongoing
policy of collaboration between the company
and the universities and technological centers.
In fact Telstar has become part of the
Hexascreen Culture Technologies university spinoff, which has an advisory scientific committee
formed by researchers connected to the
“Universidad Autónoma de Barcelona” and
“Universidad Politécnica de Cataluña”. This
alliance will enable Telstar to strengthen its ties
with the scientific community, identify advances
in research and development in the sector,
provide guidance on approaches and
technological improvements associated with
research and development in the sector, and
provide guidance on approaches and improve
technologies associated with animal cell research
in the sectors associated with life sciences.
LIFE SCIENCE SOLUTIONS - Pharma
LIFE SCIENCE SOLUTIONS - Pharma
Integrating ergonomic trials into the design process
Telstar develops isolated lyophilizer loading/unloading
system for bulk product
The Centre of Technology for Telstar's Containment equipment solutions is based in Telstar ACE, in
Dewsbury (near Leeds) in the UK.
Containment involves separating production
operators from the potential hazards of the
material being handled, necessitating close
attention at the design stage to the human
aspects of the process which is to be carried out.
Central to the design process is an evaluation of
process containment ergonomic issues. In one
report a leading pharmaceutical company
stated that almost 25% of all lost time illnesses
were caused by issues related to ergonomics.
Telstar ACE places great emphasis on the need
to perform ergonomic trials and recommends
they be used at an early stage in projects to
identify potential issues prior to designs being
frozen. The trials involve construction of a
full-scale model of the containment equipment.
Representatives of the user-group then
configure the model as closely as possible with
the required tooling and instruments and
perform the process steps on a trial basis. Such
models were constructed and utilized in a
recently awarded project involving a series of
aseptic processing steps for the freeze-drying
and final packing of a bulk sterile antibiotic. The
production line includes process equipment
integrated with RABs and isolator units which
assure the ISO 5 environment required. The
ergonomic trials for the project were conducted
at the Telstar ACE factory in Dewsbury during
which all operational and functional
requirements were agreed with the client prior
to detailed design stage.
Telstar ACE welcomes new Technical Manager
The ongoing growth of Telstar ACE has necessitated a continuous recruitment drive and the latest addition
to the management team is Michael Mellor in the role of Technical Manager at the Telstar ACE centre of
technology in Dewsbury, UK.
Michael joins the Telstar
ACE team from
competitor Howorth Air
Technology and brings
with him over 15 years of
experience in the
containment industry.
Michael has successfully
managed large scale installations providing
innovative solutions to containment problems
for a variety of pharmaceutical clients in various
locations around the world, Michael has
already been hard at work establishing a
program of technical developments focused on
improving quality and extending functionality
of Telstar ACE isolators from design through
manufacturing and assembly methods.
Throughout 2010, as part of the Telstar Group
R & D plans, Telstar ACE will contribute to the
development of a new range of Sterile and
Aseptic systems constructed to modular
designs with pre-engineered options able to
address a broad range of applications.
Increasing and developing the engineering
capability is also a priority for Michael, who has
already brought in additional resource to
broadening the experience base of the
engineering team.
This entire program is bringing fresh and
innovative technology to the Telstar ACE
portfolio of equipment solutions, helping assure
Telstar's reputation as a global leader in the field
of containment in the years ahead.
Telstar broadens its industrial freeze-dryer product range
Telstar has broadened its industrial freeze-dryer product range to better address the increasing diversity of
GMP pharmaceutical production on a global scale.
The new range of equipment and associated
options enable Telstar to more rapidly develop a
solution to match a client application.
Due to the increasing requirements to automate
the loading and unloading of freeze-dryers in
combination with the use of isolation technology
to protect the operator and help assure aseptic
conditions, the freeze-dryer has become only
one element of an integrated processing system.
Lyonomic 3D image.
Telstar is in a unique position to address this
demand by bringing together its own in-house
technologies in the form of the new Lyomega; a
full customized, integrated and automated
aseptic freeze-drying solution.
At the same time Telstar has recognized that
some clients require a more standard approach,
so that freeze-drying capacity can be provided
quickly and cost effectively. To address this type
of applications Telstar has developed the
Lyonomic, a new standard series of freeze-dryer
which provides a very reliable and proven
solution made economical through modular
design configurable with a broad range of preengineered options and easy to install.
Lyomega and Lyonomic are two new and
unique concepts: Lyomega represents complete
customized solutions while Lyonomic facilitates
cost-effective standard production. Together
they provide a broad family of solutions to
address all GMP industrial freeze-drying
applications in the globally diverse and dynamic
pharmaceutical market.
Lyomega 3D image.
Products processed by lyophilization are becoming increasingly potent, necessitating strict segregation
between the operator and the processing area in order to mitigate the health risk.
One practical method by which this can be
achieved is by placing a physical barrier
known as a containment isolator between
product and operator.
Telstar has just delivered an automated
system for the lyophilization of a bulk
polypeptide which is hazardous to
operators. The system enables an OEL
3
(Operator Exposure Level) of 1 µg/m to be
achieved over an eight-hour shift. The system
provided is comprised of a GMP productionscale lyophilizer and a loading unloading
system housed within a three-chamber
mobile Isolator system.
After the product has been lyophilized the
dry product is removed from the trays using
vacuum, which transports the product to a
cyclone where it is separated from the
airstream and collected in a hopper for
transfer to the next step in the production
process.
Telstar was uniquely suited to providing this
system; being able to develop a process
solution and then provide all of the required
technology using the resources of the Telstar
Group.
The technology developed is able to be
applied to both aseptic and non-aseptic
environments and the solution has already
attracted the attention of other Telstar clients
who have also placed orders for similar
equipment.
Implementation of this complex integrated
project was achieved through the close
collaboration of three Telstar Technology
Centers: Lyophilization, based in Terrassa,
Spain; Containment, based in Dewsbury,
UK, and; Loading Systems, based in Bristol,
Pennsylvania in the USA. In addition, one of
Telstar's partners, the Danish company
Flexicon, provided the peristaltic filling
technology used to dispense the liquid
product into stainless steel trays.
2. The Operator places trays at each of two
filling stations within the Transfer Chamber.
The trays are automatically filled with the
required volume of product and then
automatically transferred through the Pizza
Door onto the shelf of the Lyophilizer (which
is equipped to position each of its shelves at a
constant height for loading). This process
continues until the entire Lyophilizer has
been filled.
3. The Pizza Door is closed and the
Lyophilization Cycle is performed. At the end
of the cycle the Isolator system is closed (if
they were open during the loading process)
the environmental control is made
operational and a leak test is carried out.
4. The chamber of the Lyophilizer is brought
to the same pressure as the Isolator system,
the Pizza Door is opened and pairs of trays
are automatically removed from the
Lyophilizer and positioned in front of the
operator. Using a vacuum wand and working
through Glove Ports, the Operator removes
the dry product from the trays and then
places the empty trays into storage racks in
the Tray Storage Chambers.
Figure 1: The three-chamber mobile Isolator
houses the Loading/Unloading System
which is shown attached to the front of the
Lyophilizer.
The central 'Transfer Chamber' contains the
mechanisms which automatically transfer
the trays of product into and out of the
process chamber of the Lyophilizer through
an automatic sliding door referred to as a
'Pizza Door'. On each side of the Transfer
Chamber are separate 'Tray Storage
Chambers'. The Transfer Chamber docks to a
flange on the front of the Lyophilizer and is
made leak tight by an inflatable gasket. The
Tray Storage Chambers are similarly
attached to the Transfer Chamber and once
connected the three chambers make up the
Isolator system, with integrated
environmental control provided to all three
chambers.
product to be handled is safe in liquid form
and hazardous only in dry form then it is
possible to perform the loading operation
without the need for containment.)
Figure 2: The internal surfaces of the Loading
System are decontaminated using a misting process.
5. This process continues until all of the trays
have been removed from the Lyophilizer,
after which the Pizza Door is closed. At this
point in the process the product has been
removed and securely stored.
6. The internal surfaces of the Isolator system
and the Lyophilizer are potentially
contaminated with hazardous product.
While all Chambers are still docked in place
and leak-tight the entire internal surface of
the equipment and the trays are
decontaminated using an atomized misting
process (see Figure 2). Any gross spillage of
product can be removed by the operator
using a hand-held spray nozzle (see Figure 3).
Figure 3: Manual cleaning operations.
The Process Steps...
1. The Transfer Chamber is docked to the
front of the Lyophilizer and in turn the two
Tray Storage Chambers are docked to the
sides of the Transfer Chamber. (Note: If the
7. The loading equipment has now been
made safe and the elements can be
undocked for thorough manual cleaning.
The Lyophilizer is subjected to fully
automated Clean-in-Place and Steam
Sterilization cycles.
8. The equipment is now ready for the next
production batch.
LIFE SCIENCE SOLUTIONS - Pharma
LIFE SCIENCE SOLUTIONS - Pharma
Integrating ergonomic trials into the design process
Telstar develops isolated lyophilizer loading/unloading
system for bulk product
The Centre of Technology for Telstar's Containment equipment solutions is based in Telstar ACE, in
Dewsbury (near Leeds) in the UK.
Containment involves separating production
operators from the potential hazards of the
material being handled, necessitating close
attention at the design stage to the human
aspects of the process which is to be carried out.
Central to the design process is an evaluation of
process containment ergonomic issues. In one
report a leading pharmaceutical company
stated that almost 25% of all lost time illnesses
were caused by issues related to ergonomics.
Telstar ACE places great emphasis on the need
to perform ergonomic trials and recommends
they be used at an early stage in projects to
identify potential issues prior to designs being
frozen. The trials involve construction of a
full-scale model of the containment equipment.
Representatives of the user-group then
configure the model as closely as possible with
the required tooling and instruments and
perform the process steps on a trial basis. Such
models were constructed and utilized in a
recently awarded project involving a series of
aseptic processing steps for the freeze-drying
and final packing of a bulk sterile antibiotic. The
production line includes process equipment
integrated with RABs and isolator units which
assure the ISO 5 environment required. The
ergonomic trials for the project were conducted
at the Telstar ACE factory in Dewsbury during
which all operational and functional
requirements were agreed with the client prior
to detailed design stage.
Telstar ACE welcomes new Technical Manager
The ongoing growth of Telstar ACE has necessitated a continuous recruitment drive and the latest addition
to the management team is Michael Mellor in the role of Technical Manager at the Telstar ACE centre of
technology in Dewsbury, UK.
Michael joins the Telstar
ACE team from
competitor Howorth Air
Technology and brings
with him over 15 years of
experience in the
containment industry.
Michael has successfully
managed large scale installations providing
innovative solutions to containment problems
for a variety of pharmaceutical clients in various
locations around the world, Michael has
already been hard at work establishing a
program of technical developments focused on
improving quality and extending functionality
of Telstar ACE isolators from design through
manufacturing and assembly methods.
Throughout 2010, as part of the Telstar Group
R & D plans, Telstar ACE will contribute to the
development of a new range of Sterile and
Aseptic systems constructed to modular
designs with pre-engineered options able to
address a broad range of applications.
Increasing and developing the engineering
capability is also a priority for Michael, who has
already brought in additional resource to
broadening the experience base of the
engineering team.
This entire program is bringing fresh and
innovative technology to the Telstar ACE
portfolio of equipment solutions, helping assure
Telstar's reputation as a global leader in the field
of containment in the years ahead.
Telstar broadens its industrial freeze-dryer product range
Telstar has broadened its industrial freeze-dryer product range to better address the increasing diversity of
GMP pharmaceutical production on a global scale.
The new range of equipment and associated
options enable Telstar to more rapidly develop a
solution to match a client application.
Due to the increasing requirements to automate
the loading and unloading of freeze-dryers in
combination with the use of isolation technology
to protect the operator and help assure aseptic
conditions, the freeze-dryer has become only
one element of an integrated processing system.
Lyonomic 3D image.
Telstar is in a unique position to address this
demand by bringing together its own in-house
technologies in the form of the new Lyomega; a
full customized, integrated and automated
aseptic freeze-drying solution.
At the same time Telstar has recognized that
some clients require a more standard approach,
so that freeze-drying capacity can be provided
quickly and cost effectively. To address this type
of applications Telstar has developed the
Lyonomic, a new standard series of freeze-dryer
which provides a very reliable and proven
solution made economical through modular
design configurable with a broad range of preengineered options and easy to install.
Lyomega and Lyonomic are two new and
unique concepts: Lyomega represents complete
customized solutions while Lyonomic facilitates
cost-effective standard production. Together
they provide a broad family of solutions to
address all GMP industrial freeze-drying
applications in the globally diverse and dynamic
pharmaceutical market.
Lyomega 3D image.
Products processed by lyophilization are becoming increasingly potent, necessitating strict segregation
between the operator and the processing area in order to mitigate the health risk.
One practical method by which this can be
achieved is by placing a physical barrier
known as a containment isolator between
product and operator.
Telstar has just delivered an automated
system for the lyophilization of a bulk
polypeptide which is hazardous to
operators. The system enables an OEL
3
(Operator Exposure Level) of 1 µg/m to be
achieved over an eight-hour shift. The system
provided is comprised of a GMP productionscale lyophilizer and a loading unloading
system housed within a three-chamber
mobile Isolator system.
After the product has been lyophilized the
dry product is removed from the trays using
vacuum, which transports the product to a
cyclone where it is separated from the
airstream and collected in a hopper for
transfer to the next step in the production
process.
Telstar was uniquely suited to providing this
system; being able to develop a process
solution and then provide all of the required
technology using the resources of the Telstar
Group.
The technology developed is able to be
applied to both aseptic and non-aseptic
environments and the solution has already
attracted the attention of other Telstar clients
who have also placed orders for similar
equipment.
Implementation of this complex integrated
project was achieved through the close
collaboration of three Telstar Technology
Centers: Lyophilization, based in Terrassa,
Spain; Containment, based in Dewsbury,
UK, and; Loading Systems, based in Bristol,
Pennsylvania in the USA. In addition, one of
Telstar's partners, the Danish company
Flexicon, provided the peristaltic filling
technology used to dispense the liquid
product into stainless steel trays.
2. The Operator places trays at each of two
filling stations within the Transfer Chamber.
The trays are automatically filled with the
required volume of product and then
automatically transferred through the Pizza
Door onto the shelf of the Lyophilizer (which
is equipped to position each of its shelves at a
constant height for loading). This process
continues until the entire Lyophilizer has
been filled.
3. The Pizza Door is closed and the
Lyophilization Cycle is performed. At the end
of the cycle the Isolator system is closed (if
they were open during the loading process)
the environmental control is made
operational and a leak test is carried out.
4. The chamber of the Lyophilizer is brought
to the same pressure as the Isolator system,
the Pizza Door is opened and pairs of trays
are automatically removed from the
Lyophilizer and positioned in front of the
operator. Using a vacuum wand and working
through Glove Ports, the Operator removes
the dry product from the trays and then
places the empty trays into storage racks in
the Tray Storage Chambers.
Figure 1: The three-chamber mobile Isolator
houses the Loading/Unloading System
which is shown attached to the front of the
Lyophilizer.
The central 'Transfer Chamber' contains the
mechanisms which automatically transfer
the trays of product into and out of the
process chamber of the Lyophilizer through
an automatic sliding door referred to as a
'Pizza Door'. On each side of the Transfer
Chamber are separate 'Tray Storage
Chambers'. The Transfer Chamber docks to a
flange on the front of the Lyophilizer and is
made leak tight by an inflatable gasket. The
Tray Storage Chambers are similarly
attached to the Transfer Chamber and once
connected the three chambers make up the
Isolator system, with integrated
environmental control provided to all three
chambers.
product to be handled is safe in liquid form
and hazardous only in dry form then it is
possible to perform the loading operation
without the need for containment.)
Figure 2: The internal surfaces of the Loading
System are decontaminated using a misting process.
5. This process continues until all of the trays
have been removed from the Lyophilizer,
after which the Pizza Door is closed. At this
point in the process the product has been
removed and securely stored.
6. The internal surfaces of the Isolator system
and the Lyophilizer are potentially
contaminated with hazardous product.
While all Chambers are still docked in place
and leak-tight the entire internal surface of
the equipment and the trays are
decontaminated using an atomized misting
process (see Figure 2). Any gross spillage of
product can be removed by the operator
using a hand-held spray nozzle (see Figure 3).
Figure 3: Manual cleaning operations.
The Process Steps...
1. The Transfer Chamber is docked to the
front of the Lyophilizer and in turn the two
Tray Storage Chambers are docked to the
sides of the Transfer Chamber. (Note: If the
7. The loading equipment has now been
made safe and the elements can be
undocked for thorough manual cleaning.
The Lyophilizer is subjected to fully
automated Clean-in-Place and Steam
Sterilization cycles.
8. The equipment is now ready for the next
production batch.
VACUUM SOLUTIONS
LIFE SCIENCE SOLUTIONS - Laboratory
Efficient Home Energy, belonging to the Mondragón group, manufactures the Stirling energy microgeneration
boiler.
This is a normal-sized domestic boiler with a
combined heat and electricity
microgenerating system, running on gas,
which besides covering domestic heating and
hot water needs also generates electricity.
Its impellers are capable of reducing home
energy bills by over 20%, and cutting CO2-
emissions by up to a tonne a year per
household.
The Stirling principle comes from an invention
in 1816 by a Scottish religious minister of that
name. Basically it is a motor which runs on hot
air. The expansion induced within a gas moves
a working piston which drives a dynamo.
With domestic heating boilers, use is made of
the combustion exhaust gases which are lost
up the flue. The movement of the pistons is
converted into electricity generation which is
fed into the grid. It is therefore an “energy
saving” system which means energy can be
saved in every home.
Telstar launches new generation of more
compact biological safety cabinets that optimize
laboratory space
!
ew
N
Telstar Vacuum Solutions supply leak detection
equipment for Stirling motors
Telstar has released an innovative cabinet design, which maintains work
space while making the chassis up to 20% smaller than the market average.
Telstar has developed a new generation of
biological safety cabinets, which are more
compact and optimise the usable work area in
laboratories with limited space. Intended for
the laminar flow manipulation of
microorganisms with biological risk levels 2
and 3, the new range of Telstar Bio II Advance
cabinets offers an ergonomic design that
adapts easily to small spaces, especially in
laboratories with low ceilings and where
various pieces of equipment need to be used
in the same area.
With all the features of a high-end cabinet, the
Bio II Advance is designed to protect the user,
the sample and the environment, and is
notable for its reduced external dimensions
while maintaining an optimum inner work
space. With a width of 759 mm, the height of
the Bio II Advance is up to 20% less than the
market average.
The Bio II Advance also incorporates
improvements in airflow efficiency. The
reduction of the air path in an optimised
plenum, combined with automatic
microprocessor control, keeps the laminar
flow constant and avoids energy loss, reducing
heat dissipation and extending the useful life of
the filter. As for energy efficiency, this range of
cabinets has an Eco Mode function, whereby
the cabinet can be put on standby, which
keeps the sample protected inside the cabinet
while the user performs other tasks, saving
energy, reducing residual heat and prolonging
the useful life of the filters. Finally, in this range
of biosafety cabinets, Telstar has incorporated
the 4F system (Fast, Friendly and eFFicient), a
patented system that makes it possible to
replace the filter in just five minutes thanks to
quick access via the front of the cabinet.
N
ew
!
Telstar introduces into the international market
the first minibioreactors allowing multiple
simultaneous cell culture trials
Telstar incorporates Ferran Costas as General Manager of
Telstar Vacuum Solutions
Ferran Costas has joined the Telstar Group as general manager of Telstar Vacuum Solutions.
Ferran is a Telecommunications Engineer
specialising in the
development of specific
projects for the
aerospace sector, with
an MBA from Esden
(Madrid).
Ferran brings with him a wealth of experience
in the design and development of
RF/microwave equipment and sub-systems for
satellites such as Hispasat-Amazonas, Galileo,
SMOS, ICO, Terrestar, Globalstar-2, etc. His
professional career includes positions with
Mier Communications, which designs and
produces radio frequency communication
equipment and systems, as well as with
Ingenieria de Radiofrecuencias (Radio
Frequency Engineering) – IRSA, TRACOR SA,
Radiación Microondas SA (Microwave
Radiation) – RYMSA, where he acted as
deputy general manager, and Arthur Andersen.
In his new role with Telstar Vacuum Solutions,
Ferran will direct Group strategy in the field of
high vacuum and ultra high vacuum project
development to consolidate the Group's
position in the international market and
reinforce the growth plans in the hightechnology energy, aerospace and scientific
research industries market. The focus will be
on development of high added value products
and projects with an engineering and
innovation component, specifically in the area
of space simulators for space companies,
agencies and institutions, and of large scientific
installations in various fields: nuclear fusion,
particle accelerators (synchrotrons, neutron
sources, etc.) and large telescopes (for
example, reflector recoating plants). Also,
within the framework of this new step, there
will be a commitment from Telstar Vacuum
Solutions to promote the development of
vacuum and high vacuum technology
equipment for industrial applications, in
particular those incorporating high levels of
technology.
Telstar has developed a sound track record in
the development of space technology, high
vacuum and ultra-high vacuum technology
following involvement in large scale projects
that have taken place in recent years which
have earned it international recognition and
distinction.
Of particular note is its participation in the
development of international projects, such as
synchrotrons (ESRF, ALBA), space simulation
chambers and the experimental nuclear fusion
reactor, ITER. In fact, Telstar was the first
company in the world to design and
manufacture the mechanical manipulator for
the future international reactor, ITER and
recently developed the largest space
simulation chamber in the southern
hemisphere for the Government of Brazil
(INPE).
Telstar is introducing into the market a completely innovative minibioreactor model to perform animal cell culture
screening studies on a scale applicable to R&D. Planned for 2010, this equipment will be launched on the market under
the brand name of Telstar Hexascreen.
It is the first minibioreactor on the market to
enable animal cell culture trials and
experiments on a scale of 10 to 15 m, with the
capacity to handle six cultures at a time, and a
workstation accommodating single-use
interchangeable plates to guarantee sterility
and speed up the start of the bioprocess.
The launch of this new bioreactor reinforces
Telstar's activity in the field of R&D equipment
for biotechnology applications. The new
minibioreactor will be included in the
technological development line Telstar Cell
Culture, where Telstar has plans for future
growth. Telstar is currently designing,
manufacturing and marketing other
equipment designed for pharmaceutical,
biotechnological and biomedical research, to
which it will be adding the new range of Telstar
Hexascreen minibioreactors.
The development of these minibioreactors is
the result of an alliance of synergies between
Telstar and the technology oriented company
Hexascreen Culture Technologies, which
specializes in bioreactor applications for
animal cell based processes, which Telstar
recently joined through a shareholding
acquisition.
Innovative equipment
These units offer change of medium,
monitoring and control facilities similar to
those of laboratory reactors, which enable the
collection of information on the main culture
variables, such as the temperature, dissolved
oxygen/oxygen consumption, pH, optical
density and measurement of the spectrum in
the visible range, while simultaneously
monitoring growth (absorbance) and
metabolism (indirectly from acidification/
oxygen consumption).
All these features make the Telstar Hexascreen
the most innovative equipment for the
pharmaceutical and biotechnology industry
market and research centers because:
• It offers the user reduced cost by being able
to carry out the first trials on a minimum scale
in order to ensure that the results obtained in
its cultures will be reproducible on a
production scale.
• It speeds up the bioprocess and multiples the
opportunities for experimentation by being
able to develop six simultaneous cultures.
• It facilitates the start of the bioprocess by the
use of replaceable plates which ensure sterility,
requiring the user merely to inoculate the
cultures before placing the plate in the
workstation. This innovation overcomes the
complexity of use usually found in bioreactors,
which involve laborious preparation,
sterilization and calibration processes before
the start of the cultures, often requiring highly
qualified personnel.
During 2010, Telstar will develop a new stage
in the Telstar Hexascreen minibioreactor by
incorporating the fed-batch model for growth
and increased productivity of the cell culture.
Collaboration with universities and
technological leadership
Telstar's leadership in the innovation and
development of new technologies in the field
of life sciences is the result of an ongoing
policy of collaboration between the company
and the universities and technological centers.
In fact Telstar has become part of the
Hexascreen Culture Technologies university spinoff, which has an advisory scientific committee
formed by researchers connected to the
“Universidad Autónoma de Barcelona” and
“Universidad Politécnica de Cataluña”. This
alliance will enable Telstar to strengthen its ties
with the scientific community, identify advances
in research and development in the sector,
provide guidance on approaches and
technological improvements associated with
research and development in the sector, and
provide guidance on approaches and improve
technologies associated with animal cell research
in the sectors associated with life sciences.
EDITORIAL
TPRO
Corporate Management of Key Accounts
Cristalia inaugurates a new multipurpose production plant
Telstar as a strategic technological partner of its clients.
The pharmaceutical company Cristalia, founded in 1972 and based in the city of São Paulo, has invested in
one of the most modern and innovative drug production plants in Brazil.
The globalisation of
the market has made
commonplace the
development of
complex projects
involving a large
number of partners
located across a
number of countries.
Good management of these projects
requires the free flow of communication
between each and every one of them, along
with sound internal co-ordination to achieve
the best outcome rapidly and efficiently.
The current structure of the Telstar Group,
with production plants covering different
technologies in various countries with
various representatives at the commercial
level increases the need for co-ordination to
convey information consistently and clearly.
It is in this environment that the corporate
key account manager is of utmost
importance as the link between the client's
organisation and Telstar, to provide and
ensure communication, knowledge and, in
short, client satisfaction. Telstar would like
clients to see it as a strategic technological
partner and not merely as an equipment
and/or services provider.
Telstar is growing, its clients are growing and
its project base is growing. From this
standpoint, the Telstar Group has enhanced
its organisational model, placing particular
importance on client-based management
and the creation of synergies to serve client
interests effectively and efficiently. This is an
all-embracing function that had hitherto
been developing separately but which is now
being consolidated at a global level,
promoting mutual co-ordination of all the
activities of the various Telstar companies
and centres in the field of Life Sciences and in
particular everything in relation to the
pharmaceutical and bio-technology sectors.
The main objective is, therefore, client
satisfaction through the implementation of
procedures to ensure an unrivalled service.
The Telstar motto: Focus on the client. Telstar
wants to co-ordinate actions and projects
and strive to guarantee that information
flows correctly, not only within the Telstar
organisation, but also to clients. “We will
improve clients' knowledge of our
organisation and the solutions that we can
offer them, improving our knowledge of their
organisations and requirements in order to
cement the relationship seen in the long
term. In short, we aim to create the ability to
provide a quality solution that contributes to
the growth and development of our clients”.
Toni Lorente,
Corporate Key Account Manager
TELSTAR GROUP
Telstar reinforces its commercial structure for the life
sciences market
To this end, two commercial teams working
in the Pharmaceutical Industry and
Laboratory fields will be responsible for the
promotion and sale of the whole range of
equipment, projects, systems and services
and will be able to provide complete or
individual solutions with a global and process
perspective according to market
requirements and client needs.
Currently, Telstar is one of the few company
groups in the world that can provide
integrated solutions in the process field for
the life sciences market.
This new organisation is headed by the
Corporate Sales and Marketing Director,
Jordi Puig, along with a new management
team. The Pharma team includes Toni
Lorente as Corporate Major Accounts
Director, Jordi Net as Commercial and
Marketing Director for Pharmaceutical
Industry Teams and Rafael Alvarez de Toledo
as Commercial and Marketing Director for
Project Development.
The Laboratory team consists of Chantal
Schoenmaker as Commercial Director for
Central and Northern Europe and Roser
Dalmau as Commercial Director for the Rest
of the World.
Cristalia continuously invests in offering
innovative products for the Brazilian
market. It has registered 117 patent
applications and has patents for 21
technologies and 15 drugs, making it the
national drug company with the largest
number of patents.
The management made the decision to
expand production capacity five years
ago, through the construction of a new
unit in Itapira, São Paulo. It will be the
second drug production plant on this site,
where operation is already underway in
the areas of R&D and innovation,
biotechnology and pharmaceutics. This is
in addition to the current drug plant,
2
which has over 53,000 m of constructed
surface. In order to acquire the latest
technologies for the new factory,
company management participated in
various international fairs and technical
visits in 2003 and 2004.
Through these actions, the company
established the highest standards of
architectural, material and equipment
solutions. Conceptually, the aim was to
construct a compact unit, with the
maximum level of process optimization
and functionality in space. This was
achieved by incorporating the most
modern concepts and equipment.
In the outcome, TPRO was designated by
Cristalia as the specialised company for
this development. The pharmaceutical
2
plant covers close to 11,800 m of
constructed production surface, from
2
which 3,100 m correspond to classified
areas, and the rest to technical surfaces
and controlled areas. The new facility will
allow Cristalia to double its current
production capacity.
In general terms, there are four specific
areas: sterile freeze-dried products,
sterile liquids (eyedrops), oral solids and
semi-solids (ointments). On the first floor,
most of the space is used for the
production of freeze-dried (lyophilized)
products. This comprises close to
2
1,470 m , 540 of which correspond to
classified areas and 930 to non-classified
areas. The solids production unit is the
largest of all; the production line occupies
2
2,600 m , of which 1,500 correspond to
Grade D and the rest to non-classified
areas.
The new facility of Cristalia is among the
most modern and efficient in the world
and the final result is a world class
production plant.
The United Pharmaceutical Technologies Consortium for
large process projects in the field of life sciences is being
created in Brazil
Combining the synergies that exist between Pharmaster, Tpro and SVS will bring greater competitive value to
large scale projects in the pharmaceutical industry.
The Telstar Group is reinforcing its commercial structure for the
Pharmaceutical Industry and Laboratory divisions by incorporating the
various commercial teams that hitherto have been separated along
product or geographical lines into a single sales and marketing force.
This new strategy, which enhances the
Group's ability to provide a global response
to market requirements, will bring increased
efficiency, depth and coverage to the
growing presence of the Telstar Group in the
international life sciences market.
The facility, which was officially
inaugurated last March, has increased the
production capacity of the company and
readied it for further challenges.
R. Alvarez de Toledo
T. Lorente
J. Puig
R. Dalmau
The companies Pharmaster, Tpro Engenharia
do Brasil and SVS Consulting Services have
reached an agreement to create the United
Pharmaceutical Technologies Consortium in
order to provide highly competitive solutions
for projects associated with the Life Sciences
industries.
J. Net
The combination of synergies and the
complementary attributes of the three
companies will enable the rapid
development of sound technical
solutions for the design, installation,
commissioning and evaluation of systems
critical to the pharmaceuticals, biotechnologies, cosmetics and veterinary
industries, directed in particular towards
larger and more complex projects.
C. Schoemaker
The companies making up the consortium
have a substantial penetration and presence
in the Brazilian market. Complementary
resources and know-how will bring particular
benefits to medium and large volume
projects, providing competitive advantages
derived from the combination of synergies
of the three companies. The United
Pharmaceutical Technologies Consortium
can provide the design, installation,
evaluation and commissioning of not only a
specific unit, but also a complete plant,
including engineering, installation,
evaluation and certification and
management services.
This partnership agreement does not
signify the loss of identity of any of the
companies making up the consortium. Each
one will maintain its independence and its
own commitments. In fact, each one of the
companies of the consortium will continue
to operate autonomously and independently
in the market, supporting projects of small
and medium sized companies, just as they
have been doing up to now.
EXHIBITIONS AND CONFERENCES
Conferencia
Farmacéutica,
Lodz
PharmTech,
Moscow
Biotechnica, Hannover
Analytica,
Munich
Congreso de Ingeniería
Hospitalaria,
Santiago de Compostela
SECAL Congress,
Salamanca
VWR European
Interphex NYC, Sales Meeting,
Madrid
Nueva York
International
ISPE CASA,
Congress on
Raleigh Occupational
Risk on
Health Care Sector,
Madrid
ASEBIR,
Interphex Congress
Puerto Rico, Valencia
San Juan
ISPE Annual Meeting,
San Diego
June 2010 . Number 21
Powtex,
Osaka
www.telstar.eu
China Pharm,
Shanghai
ArabLab,
Dubai
P-MEC,
Mumbai
T
G ELS
RO T
A
U R
P
Bio International
Convention,
Chicago (USA)
Telstar has acquired French company Usifroid, which is internationally recognized for the development
and supply of GMP lyophilizers for the pharmaceutical market.
FCE Pharma,
Sao Paulo (Brazil)
Expo Arpia,
Buenos Aires
2010
• Interphex Puerto Rico:
4 - 5 March, San Juan (Puerto Rico)
• ISPE CASA:
23 March, Raleigh (EEUU)
Through this acquisition, on April 9th 2010,
Telstar reinforces its position in the
international life sciences market and
consolidates its position in Europe with a
French market share of 80% in freeze drying
equipment solutions for the pharmaceutical
industry.
• Analytica Munich:
23 - 26 March, Munich (Germany)
• Bio International Convention:
3 - 6 May, Chicago (USA)
• FCE Pharma:
25 - 27 May, Sao Paulo (Brazil)
• Interphex NYC:
20 - 22 April, New York (EEUU)
• ArabLab:
9 - 12 January , Dubai (UAE)
• VWR European Sales Meeting:
22 - 23 January, Madrid (España)
Coming Exhibitions
June 2010
M
7
September 2010
T
W
T
F
S
S
1
2
3
4
5
6
8
9 10 11 12 13
14 15 16 17 18 19 20
M
6
T
7
Telstar acquires Usifroid and takes a major step
into the French market
October 2010
W
T
F
S
S
1
2
3
4
5
8
9 10 11 12
Analytica China, Shanghai (China)
M
4
T
5
W
6
T
7
F
S
S
1
2
3
8
9 10
Chillventa, Nuremberg (Germany)
13 14 15 16 17 18 19
11 12 13 14 15 16 17
21 22 23 24 25 26 27
20 21 22 23 24 25 26
18 19 20 21 22 23 24
28 29 30
27 28 29 30
Expopack, Mexico D.F. (Mexico)
This acquisition will enable the Telstar Group
to pursue its strategic growth plan while
providing the backing and financial support
to enable Usifroid in France to continue
supplying and serving its customers on the
French and international markets. Usifroid is
internationally renowned for the
development of GMP freeze dryers of
pharmaceutical applications and is
recognized for achievements in the field of
innovation, most notably for pioneering and
leading the use of liquid nitrogen (LN2)
refrigeration technology in freeze drying.
The reputation and significance of the
Usifroid brand is reflected through the
constant references to the activities of the
company therefore the Telstar Group will
retain the Usifroid brand and Usifroid
products in all the markets. Usifroid will
continue to provide new equipment under
the Usifroid brand, with specifications and
features that help characterize and define
Usifroid.
freeze drying technology, includes a wide
range of solutions orientated towards the
pharmaceutical industry such as clean air,
containment, sterilisation and water
treatment. In fact, the Telstar Group is
recognized as one of the few companies in
the world capable of supplying integrated
process solutions through in-house
technologies which address the needs of the
pharmaceutical industry.
The Telstar Group will incorporate the knowhow and experience of Usifroid so that
Usifroid equipment becomes an integral part
of the Telstar portfolio, which, in addition to
Farma Cosmetica, Bogota (Colombia)
Process Teknik, Goteburgo (Sweden)
25 26 27 28 29 30 31
China Pharm, Pekin (China)
Editorial
Corporate Management of Key Accounts
Life Science Solutions
Telstar Group
• Telstar reinforces its commercial structure for the life sciences market
Back Cover
• Exhibitions and Conferences
BioChicago 2010.
Edited by: TELSTAR TECHNOLOGIES, S.L.
Photographs: TELSTAR TECHNOLOGIES, S.L
National Book Catalogue Number: B-31419-1999
ArabLab 2010.
TELSTAR TECHNOLOGIES S.L.
Av. Font i Sagué, 55 - 08227 Terrassa (Spain)
T +34 937 361 600 F +34 937 859 342
[email protected] – www.telstar.eu
Analytica Munich 2010.
Vacuum Solutions
TPro
• Telstar Vacuum Solutions supply
leak detection equipment
for
Stirling motors.
• Cristalia inaugurates a new
multipurpose production plant.
• Telstar incorporates Ferran Costas
as General Manager of Telstar
Vacuum Solutions.
• The United Pharmaceutical
Technologies Consortium for large
process projects in the field of life
sciences is being created in Brazil.
LABORATORY
• Telstar launches new generation of
more compact biological safety
cabinets that optimize laboratory
space.
• Telstar introduces into the
international market the first
minibioreactors allowing multiple
simultaneous cell culture trials.
PHARMA
• Integrating ergonomic trials into the
design process.
• Telstar ACE welcomes new Technical
Manager.
• Telstar broadens its industrial freezedryer product range.
• Telstar develops isolated lyophilizer
loading/unloading system for bulk
product.